A.I., Crypto & Tech Stocks

Biotechnology stocks are gaining momentum as promising clinical trial results, advances in artificial intelligence (AI), and renewed merger activity attract investor attention. After a difficult stretch for the industry, analysts say a new wave of medical innovation may be creating opportunities across drug developers and the companies supplying their technology.

The iShares Biotechnology ETF (IBB) climbed 24% through October 23, 2026, following a 28% gain in 2025. Several of its holdings have more than doubled this year, with Moderna among the standout performers despite a sharp recent pullback.

Investors are increasingly focused on technologies such as messenger RNA (mRNA), genomics, precision medicine and AI-powered drug discovery. These advances could help researchers identify disease targets, develop treatments and improve the odds of bringing new medicines to market.

However, biotechnology remains a high-risk industry. Clinical trials can fail, regulatory approval is uncertain, and developing a successful drug often requires years of investment.

Why Biotechnology Is Attracting Fresh Attention

The sector previously benefited from the COVID-19 pandemic, when demand for vaccines and low interest rates helped attract capital to biotechnology companies. Moderna, Pfizer and BioNTech were among the companies that gained attention during that period.

The environment later deteriorated as vaccine demand declined, interest rates rose and many early-stage drug developers struggled to deliver successful products. Initial public offerings and acquisitions also slowed.

Now, a new generation of clinical results and technologies is helping revive interest. Analysts point to a pipeline of potential drug approvals, including cancer treatments, next-generation obesity medicines and therapies for inflammatory conditions.

Artificial intelligence is another potential catalyst. By analyzing biological data and predicting how molecules may behave, AI tools could help researchers identify promising drug candidates more efficiently. Supporters believe these capabilities could reduce some development costs and accelerate discovery, although clinical testing and regulatory review remain essential.

Promising Treatments Could Reshape Medical Care

Several recent developments illustrate why investors are watching the industry closely.

Moderna and Merck are developing a personalized melanoma treatment that combines an mRNA-based approach with Merck's Keytruda. In a late-stage clinical trial, the combination reduced the risk of cancer recurrence or death by 42% compared with Keytruda alone. The companies have indicated that they aim to seek regulatory approval and potentially launch the treatment in 2027.

In another area, AstraZeneca and Amgen reported positive late-stage trial results for Tezspire in a potential new use involving severe inflammation of the esophagus. Roche also received U.S. Food and Drug Administration approval for Enspryng as a treatment for adults with thyroid eye disease, adding another option in the rare-disease treatment landscape.

Obesity medicines are also advancing beyond the first generation of GLP-1 drugs. Eli Lilly's retatrutide, which targets three hormone receptors, produced weight loss of approximately 28% to 30% at the highest doses in studies reported by the company. Lilly planned to submit the drug for FDA approval in the first quarter of 2027.

These developments could create new commercial opportunities, but trial results do not guarantee approval, widespread adoption or financial success.

AI and Genomics Expand the Investment Landscape

Investors are also looking beyond companies that develop medicines themselves.

Illumina, a provider of DNA sequencing technology, has benefited from demand for its NovaSeq X platform and collaborations supporting precision oncology research. Another company drawing attention is 10x Genomics, which supplies instruments and tools used in cancer, immunology and neuroscience research.

These businesses provide technology that pharmaceutical companies and academic researchers can use to better understand diseases and develop more targeted therapies.

AI is increasingly becoming part of that ecosystem. Biotechnology companies are using computational tools to analyze complex datasets, identify potential drug targets and explore new approaches to treatment. Still, the commercial impact will depend on whether these tools produce reliable discoveries and translate into successful products.

Merger Activity Could Support Further Growth

Acquisitions are another factor attracting attention to biotechnology. According to BTIG analyst Jeet Mukherjee, biopharmaceutical dealmaking reached $134 billion in the first half of 2026, compared with $112 billion for all of 2025.

One reason is the approaching patent expirations of major pharmaceutical products. Research cited by the RTW Institute estimates that drugs generating approximately $180 billion in revenue will lose exclusivity by 2030.

As established medicines face competition from generics or biosimilars, large drugmakers have an incentive to acquire promising treatments and replenish their development pipelines. Companies with successful clinical programs may benefit from partnerships, licensing agreements or buyout offers, though such outcomes are far from certain.

Ways Investors Can Gain Biotechnology Exposure

Investors seeking exposure to the sector have several options, each with different levels of risk.

The iShares Biotechnology ETF tracks a market-capitalization-weighted portfolio, giving greater influence to larger companies. Its holdings include Gilead Sciences, Amgen, Vertex Pharmaceuticals and Moderna.

The SPDR S&P Biotech ETF uses an equal-weight approach, providing relatively greater exposure to smaller and midsize biotechnology businesses. Its holdings include Moderna, Natera, Twist Bioscience and Halozyme Therapeutics.

Investors interested in the industry's underlying technology may also examine companies such as Illumina and 10x Genomics. Meanwhile, analysts have highlighted smaller drug developers including Monte Rosa Therapeutics, Faeth Therapeutics and Kymera Therapeutics because of their experimental treatment programs and partnerships.

These smaller companies may offer significant upside if their research succeeds, but they can also carry substantial risks. Some have yet to bring a medicine to market, leaving their valuations highly dependent on clinical progress, financing needs and future regulatory decisions.

What Investors Should Consider Before Buying

The recent rally does not eliminate biotechnology's fundamental uncertainties. A promising study can fail in a later trial, regulators can request additional evidence, and commercial demand may fall short of expectations. Stocks can also become expensive when investor enthusiasm grows faster than a company's demonstrated business prospects.

Exchange-traded funds can spread risk across multiple companies, while individual stocks provide more targeted exposure but can be especially volatile.

For investors considering the sector, the key questions include whether a company's research has credible clinical support, how much cash it has to fund development, what milestones lie ahead and whether its valuation already reflects optimistic assumptions.

Biotechnology's innovation cycle may be creating opportunities, particularly in personalized medicine, AI-assisted discovery and treatments for major health conditions. But successful investing requires distinguishing scientific promise from proven commercial results—and recognizing that even groundbreaking research does not guarantee a winning stock.

Thank you for subscribing to the Future Download! 

If you need help with your newsletter, email our Arizona-based support team at [email protected]

👩🏽‍⚖️ Legal Stuff
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT ADVICE. Morning Download products and services are offered for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation or be relied upon as personalized financial advice. We are not financial advisors and cannot give personalized advice.  There is a risk of loss in all trading, and you may lose some or all of your original investment. Results presented are not typical.  This message may contain paid advertisements, or affiliate links.  This content is for educational purposes only.

Please review the full risk disclaimer:  MorningDownload.com/terms-of-use

Just For You: Become part of the Morning Download’s SMS Community. Text “GO” to 844-991-2099 for immediate access to special offers and more!